Germany-based pharmaceutical giant Bayer AG (ETR: BAYN) has announced the initiation of a Phase I study to assess the preliminary efficacy and safety of its BAY3498264, a selective SOS1 inhibitor, when combined with sotorasib in patients with advanced KRAS G12C-mutated solid tumors.
BAY3498264: A Potential Therapeutic Agent for KRAS-Mutant Cancers
BAY3498264 is being investigated for its potential as a therapeutic agent in treating KRAS-mutant cancers, which include aggressive forms such as non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. When combined with a KRAS targeting agent like sotorasib, BAY3498264 may enhance the treatment efficacy for patients with these mutations.
The Significance of the Study
This Phase I study is a crucial step in evaluating the safety and preliminary efficacy of the combination therapy. It aims to provide valuable insights into how BAY3498264 and sotorasib can work together to target KRAS G12C-mutated tumors, which have historically been challenging to treat effectively. The study’s findings could pave the way for new treatment options for patients with these specific genetic mutations, offering hope for improved outcomes in the future.-Fineline Info & Tech
